Latest DDD-exit: Radioactive antibody for treatment of aggressive cancer

A new antibody might be the first effective treatment for Anaplastic thyroid cancer (ATC), a very aggressive cancer type with a median survival of only 4-5 month even with available treatments. The radiolabeled antibody is the result of a four-year long successful collaboration between SciLifeLab researcher Marika Nestor (Uppsala University) and the SciLifeLab Drug Discovery and Development (DDD) platform.

Read the full SciLifeLab news item here.